MeiraGTx Holdings PLC (NASDAQ:MGTX) CFO Sells $204,480.00 in Stock

MeiraGTx Holdings PLC (NASDAQ:MGTX - Get Free Report) CFO Richard Giroux sold 24,000 shares of MeiraGTx stock in a transaction dated Tuesday, July 22nd. The stock was sold at an average price of $8.52, for a total value of $204,480.00. Following the completion of the sale, the chief financial officer directly owned 853,494 shares in the company, valued at $7,271,768.88. This trade represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

MeiraGTx Stock Performance

Shares of NASDAQ:MGTX traded down $0.18 on Thursday, hitting $8.31. 263,425 shares of the company were exchanged, compared to its average volume of 564,420. The stock's 50 day moving average price is $6.72 and its 200 day moving average price is $6.51. MeiraGTx Holdings PLC has a 1-year low of $3.85 and a 1-year high of $8.98. The company has a current ratio of 1.53, a quick ratio of 1.51 and a debt-to-equity ratio of 2.34.

MeiraGTx (NASDAQ:MGTX - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.13). MeiraGTx had a negative return on equity of 241.05% and a negative net margin of 484.90%. The company had revenue of $1.93 million for the quarter, compared to analyst estimates of $4.44 million. Equities analysts expect that MeiraGTx Holdings PLC will post -1.48 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in MGTX. GAMMA Investing LLC grew its position in MeiraGTx by 3,606.7% during the 1st quarter. GAMMA Investing LLC now owns 4,448 shares of the company's stock worth $30,000 after purchasing an additional 4,328 shares during the last quarter. Summit Investment Advisors Inc. increased its stake in MeiraGTx by 106.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,871 shares of the company's stock valued at $30,000 after purchasing an additional 2,515 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of MeiraGTx by 68.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,975 shares of the company's stock worth $30,000 after buying an additional 2,016 shares during the last quarter. CWM LLC raised its position in MeiraGTx by 1,737.7% during the first quarter. CWM LLC now owns 8,674 shares of the company's stock worth $59,000 after acquiring an additional 8,202 shares during the last quarter. Finally, Ieq Capital LLC purchased a new stake in shares of MeiraGTx in the first quarter valued at about $83,000. Institutional investors and hedge funds own 67.48% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Chardan Capital dropped their price objective on MeiraGTx from $38.00 to $35.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Wall Street Zen upgraded MeiraGTx from a "sell" rating to a "hold" rating in a research report on Saturday, July 5th.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.